Plainsboro, N.J. – – September 29, 2026 -- Novo Nordisk reported that adults with type 2 diabetes who escalated their semaglutide dose to 2 mg showed a statistically significant 6% lower risk of major adverse cardiovascular events (MACE) compared with patients who switched to tirzepatide, according to real-world data presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026 in Milan.
Retrospective analysis covers 636,525 patients on semaglutide 1 mg
The COMPETE SWITCH Cardiovascular study used Komodo Health's Healthcare Map claims database, spanning January 2018 to September 2025, to compare outcomes for patients escalating from semaglutide 1 mg to 2 mg against those switching to tirzepatide at doses up to 15 mg. The cardiovascular cohort included 185,705 adults who escalated to semaglutide 2 mg and 23,104 who switched to tirzepatide, tracked via an intention-to-treat approach for death, heart attack, and stroke.
Adjusted hazard ratio shows consistent cardiovascular benefit
The adjusted hazard ratio for MACE favored semaglutide dose escalation at 1.06 (95% CI 1.04-1.08; P=0.005). A subset analysis restricted to patients with multiple baseline HbA1c or weight measurements produced a comparable result (Adjusted HR 1.07; 95% CI 1.01-1.13; P0.035), reinforcing the primary finding across a more clinically characterized population.
Treatment intensification patterns shift over two-year follow-up
At 365 days post-index, 67.2% of patients remained on semaglutide 1 mg, 29.2% had escalated to 2 mg, and 3.6% had switched to tirzepatide. By 720 days, the share remaining on 1 mg fell to 57.4%, while escalation to 2 mg rose to 36.9% and tirzepatide switches increased to 5.7%. Among those who switched to tirzepatide, roughly 31% reached a dose of 10 mg or higher during follow-up.
Novo executive frames findings as guidance for clinical decision-making
"These real-world findings can help provide insights into how intensification strategies may affect cardiovascular outcomes as an important factor in patient care," said Michael Radin, MD, executive medical director at Novo Nordisk. Kathryn S. Tierney of Middlesex Health MultiSpecialty Group added that the data reinforce weighing cardiovascular outcomes alongside glycemic control when adjusting therapy for patients already tolerating semaglutide.
Study limitations temper causal claims
Novo Nordisk noted the retrospective claims-based design carries risk of residual unmeasured confounding and may exclude patients with intermittent insurance coverage, limiting generalizability. Safety outcomes were not assessed in this analysis, and the company stated that associations shown cannot establish direct causation. Semaglutide carries a boxed warning for potential thyroid tumors, including cancer, and is contraindicated for patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
The findings build on an earlier COMPETE SWITCH analysis presented at the American Diabetes Association Scientific Sessions in June 2026, which examined HbA1c and weight loss outcomes between the same treatment pathways.